Sage Therapeutics (SAGE) Competitors $9.15 -0.02 (-0.16%) As of 01:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. APLS, NAMS, TWST, DNLI, KNSA, AGIO, RXRX, CGON, VCEL, and BEAMShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), Vericel (VCEL), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Its Competitors Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Denali Therapeutics Kiniksa Pharmaceuticals International Agios Pharmaceuticals Recursion Pharmaceuticals CG Oncology Vericel Beam Therapeutics Sage Therapeutics (NASDAQ:SAGE) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Do analysts recommend SAGE or APLS? Sage Therapeutics presently has a consensus price target of $8.75, suggesting a potential downside of 4.46%. Apellis Pharmaceuticals has a consensus price target of $39.84, suggesting a potential upside of 102.89%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 1 Sell rating(s) 16 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.94Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62 Is SAGE or APLS more profitable? Apellis Pharmaceuticals has a net margin of -28.83% compared to Sage Therapeutics' net margin of -747.63%. Sage Therapeutics' return on equity of -68.99% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-747.63% -68.99% -60.67% Apellis Pharmaceuticals -28.83%-99.19%-25.35% Do institutionals & insiders have more ownership in SAGE or APLS? 99.2% of Sage Therapeutics shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor SAGE or APLS? In the previous week, Apellis Pharmaceuticals had 2 more articles in the media than Sage Therapeutics. MarketBeat recorded 7 mentions for Apellis Pharmaceuticals and 5 mentions for Sage Therapeutics. Apellis Pharmaceuticals' average media sentiment score of 0.84 beat Sage Therapeutics' score of 0.27 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sage Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Apellis Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SAGE or APLS? Sage Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Which has preferable earnings and valuation, SAGE or APLS? Apellis Pharmaceuticals has higher revenue and earnings than Sage Therapeutics. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$47.40M12.09-$400.67M-$5.80-1.58Apellis Pharmaceuticals$775.84M3.18-$197.88M-$1.79-10.97 SummaryApellis Pharmaceuticals beats Sage Therapeutics on 13 of the 17 factors compared between the two stocks. Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.30M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.5820.3528.6119.64Price / Sales12.09304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book1.207.718.185.63Net Income-$400.67M-$55.11M$3.23B$257.73M7 Day Performance-0.49%0.68%-0.25%0.07%1 Month Performance0.94%8.22%5.40%8.32%1 Year Performance-24.71%-2.64%26.35%13.78% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics3.4162 of 5 stars$9.16-0.2%$8.75-4.5%-22.3%$573.30M$47.40M-1.58690APLSApellis Pharmaceuticals4.2319 of 5 stars$17.42-4.6%$39.79+128.4%-51.6%$2.19B$781.37M-9.73770News CoverageAnalyst ForecastAnalyst RevisionNAMSNewAmsterdam Pharma2.7421 of 5 stars$19.46-2.0%$42.89+120.4%+7.3%$2.18B$45.56M-10.354TWSTTwist Bioscience4.1837 of 5 stars$35.59-6.8%$50.40+41.6%-35.2%$2.13B$312.97M-10.95990DNLIDenali Therapeutics4.6079 of 5 stars$14.25-3.0%$33.71+136.6%-39.3%$2.07B$330.53M-5.34430Positive NewsKNSAKiniksa Pharmaceuticals International3.5027 of 5 stars$27.95+0.3%$38.80+38.8%+30.0%$2.04B$481.17M-111.80220Upcoming EarningsAGIOAgios Pharmaceuticals4.3842 of 5 stars$35.21-2.4%$58.60+66.4%-16.5%$2.04B$36.50M3.13390News CoverageAnalyst RevisionRXRXRecursion Pharmaceuticals1.8114 of 5 stars$4.93-6.5%$7.00+42.0%-36.3%$2.00B$59.82M-2.79400High Trading VolumeCGONCG Oncology2.5882 of 5 stars$26.25-2.4%$58.67+123.5%-31.9%$2.00B$662K-17.3861News CoveragePositive NewsAnalyst ForecastVCELVericel3.691 of 5 stars$39.41-5.6%$61.14+55.1%-25.6%$1.98B$237.22M1,314.10300News CoveragePositive NewsBEAMBeam Therapeutics2.2702 of 5 stars$19.18-4.1%$48.75+154.2%-23.6%$1.93B$63.52M-4.16510 Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Twist Bioscience Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Agios Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors CG Oncology Competitors Vericel Competitors Beam Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
